{"entity":{"id":"tagworks-pharmaceuticals","kind":"company","name":"Tagworks Pharmaceuticals","aka":["Tagworks Pharmaceuticals BV"],"tldr":"Tagworks Pharmaceuticals makes antibody-drug conjugates whose cancer-killing payload is released only when a second, separately injected molecule reaches the tumour. Its first product, TGW101, is in an early trial in advanced solid tumours.","summary":"Tagworks Pharmaceuticals BV is a Nijmegen, Netherlands, company with operations in the United States that pioneered Click-to-Release, a bioorthogonal chemistry in which a click reaction in the body cleaves a linker to release or deactivate a payload. Co-founded by Marc Robillard and Raffaella Rossin, it builds on click chemistry work recognised by the 2022 Nobel Prize and on the work of Joseph Fox at the University of Delaware. The approach lets antibody-drug conjugates act on non-internalising targets. TGW101 combines a TAG-72-binding diabody conjugated through a TCO linker to the MMAE payload with a separately dosed small-molecule trigger (TRG001) that releases MMAE in the tumour microenvironment. TGW211 is a HER2-directed radioimmunoconjugate whose circulating radioactivity can be cleared after tumour uptake; its CleavHER phase 0/1 imaging study is sponsored by Radboud University Medical Center. Its first registered cancer trial, NCT06959706, a first-in-human phase 1 dose-escalation study of TGW101 in advanced solid tumours at US sites, was posted on ClinicalTrials.gov in May 2025 after FDA clearance of the IND in April 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.tagworkspharma.com/"},{"label":"FDA IND clearance and phase 1 start for TGW101, April 2025","url":"https://www.tagworkspharma.com/tagworks-fda-clearance-phase1-tgw101-keith-orford-cmo"},{"label":"CleavHER phase 0/1 trial of TGW211, October 2025","url":"https://www.tagworkspharma.com/tagworks-phase-0-1-clinical-trial-tgw211-her2-radiopharmaceutical"},{"label":"ClinicalTrials.gov: phase 1 trial of TGW101 in advanced solid tumours (NCT06959706)","url":"https://clinicaltrials.gov/study/NCT06959706"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","radiopharma"],"technologies":["adc","radioimmunotherapy"],"targets":["her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and financing amounts are not stated on the company website.","Investors are inferred from board seats listed on the company's About page (Gilde Healthcare and Novartis Venture Fund, also Ysios Capital, NEA and Lightstone Ventures, which have no OnCo investor records).","OnCo has no target record for TAG-72, so only HER2 (for TGW211) is linked.","Company website and press releases read on 29 October 2026."],"hq":"Nijmegen","country":"NL","companyType":"biotech","website":"https://www.tagworkspharma.com/","stage":"growth","investors":["gilde-healthcare","novartis-venture-fund"],"funding":[]},"route":"/companies/tagworks-pharmaceuticals/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"gilde-healthcare","kind":"company","name":"Gilde Healthcare","route":"/companies/gilde-healthcare/"},{"id":"novartis-venture-fund","kind":"company","name":"Novartis Venture Fund","route":"/companies/novartis-venture-fund/"}]}}